BG
MRSN

Bellevue Group’s Mersana Therapeutics MRSN Stock Holding History

Bellevue Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-208,745
Closed -$6.63M – 171
2023
Q3 		$6.63M Sell
208,745
-32
-0% -$1.52K 0.11% 96
2023
Q2 		$17.2M Buy
208,777
+36,792
+21% +$5.38M 0.24% 83
2023
Q1 		$17.7M Buy
171,985
+681
+0.4% +$95.6K 0.26% 84
2022
Q4 		$25.1M Buy
171,304
+8,000
+5% +$1.35M 0.33% 77
2022
Q3 		$27.6M Buy
163,304
+7,496
+5% +$1.22M 0.4% 67
2022
Q2 		$18M Sell
155,808
-2,352
-1% -$221K 0.25% 90
2022
Q1 		$15.8M Sell
158,160
-8,400
-5% -$981K 0.18% 98
2021
Q4 		$25.9M Sell
166,560
-3,880
-2% -$755K 0.27% 93
2021
Q3 		$40.2M Buy
170,440
+52,800
+45% +$15.4M 0.41% 78
2021
Q2 		$39.9M Buy
117,640
+3,640
+3% +$1.38M 0.39% 79
2021
Q1 		$46.1M Buy
114,000
+36,960
+48% +$17.9M 0.49% 66
2020
Q4 		$51.3M Buy
+77,040
New +$42.8M 0.59% 52

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return